Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study of possible anticancer drug reveals new mechanism of gene regulation

20.12.2002


Researchers at Washington University School of Medicine in St. Louis have discovered a possible new mechanism for regulating large groups of genes. While conducting yeast research on a potential new anticancer drug, the team identified a mechanism that enables the genome to silence large numbers of genes simultaneously, rather than each gene individually.



The finding emerged during research studying the molecular action of the drug rapamycin. Rapamycin currently is used to suppress the immune system following kidney transplantation, but it also is being investigated as a promising anticancer drug. Rapamycin stops tumor-cell growth through a mechanism unlike those used by other anticancer drugs. The findings are published in the December issue of Molecular Cell.

"This study shows how basic research can have a clinical impact," says study leader X. F. Steven Zheng, Ph.D., assistant professor of pathology and immunology. "It gives us insights into the molecular mechanism of rapamycin’s antitumor activity and may provide new targets for drug development."


As an immunosuppressant, rapamycin is different from other drugs. While other immunosuppressants tend to promote the growth of cancer cells, rapamycin blocks the proliferation of tumors. In addition, rapamycin blocks the development of blood vessels in tumors, a process known as angiogenesis. These features led doctors to test its use as an anticancer drug.

"For a single drug to block both tumor proliferation and angiogenesis is unique," says Zheng, who is an investigator with the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Test-tube experiments done by others showed that rapamycin binds to a large, previously unknown cell protein known as target of rapamycin (TOR). TOR is found in organisms from yeast to humans, suggesting that it may serve an essential purpose in cells.

Zheng and colleagues used rapamycin to inactivate TOR, enabling them to examine both TOR’s function in the cell and how rapamycin works.

The researchers identified about 300 yeast genes involved in TOR-related activities. The product of one of these genes, a protein known as silent information regulator 3 (Sir3), normally clings to a battery of genes responsible for a stress protein, thereby keeping the genes inactive and silent. Stress proteins are molecules produced by cells during adverse growing conditions.

But the researchers found that when rapamycin inactivates TOR, Sir3 molecules detach from the line of stress-protein genes, triggering a stress response: The cells begin producing stress proteins, their walls thicken and they stop proliferating.

"This surprised us," Zheng says. "TOR was not known to be directly involved in stress control. Also, this means of silencing many genes simultaneously suggests a new type of gene regulation." Usually, genes are turned on or off individually by proteins targeted to specific genes, he says.

Furthermore, the investigators found that when rapamycin inactivates TOR, it also shuts down nutrient processing pathways, preventing yeast cells from using glucose to produce energy and amino acids to make new proteins.

Overall, the researchers conclude that when rapamycin inhibits TOR, it triggers a variety of responses, including stress and starvation responses. Together, these actions probably cause the cells to stop proliferating.

These insights into rapamycin’s action must now be verified in human cells.


Ai W, Bertram PG, Tsang CK, Chan T-F, Zheng XFS. Regulation of subtelomeric silencing during stress response. Molecular Cell, December 2002.

Funding from the National Institutes of Health supported this research.

Darrell E. Ward | EurekAlert!
Further information:
http://medinfo.wustl.edu/

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>